Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults

OBJECTIVE: Children and adolescents with recurrent and metastatic solid tumors have a poor outcome. A previous phase 1 study (ANGIO1) targeting angiogenesis with bevacizumab, sorafenib, and cyclophosphamide, demonstrated a signal of activity in a subset of patients. Here we report the results of a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bodea, Jessica, Caldwell, Kenneth J., Federico, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174993/
https://www.ncbi.nlm.nih.gov/pubmed/35692751
http://dx.doi.org/10.3389/fonc.2022.864790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174993/
https://www.ncbi.nlm.nih.gov/pubmed/35692751
http://dx.doi.org/10.3389/fonc.2022.864790

Ejemplares similares